Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
457 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,480 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 |
| clinicaltrials |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer | withdrawn | Phase 2 | 0 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Sep 10, 2014 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials